Results of radioiodine (131/125I) therapy of hyperthyroidism

One individually calculated dose of 131I was sufficient to control the hyperfunction in 75% of the patients with Graves' disease and 85% of the patients with autonomous adenoma. The cumulative myxedema risk 10 years after therapy was: 15% in the patients with Graves' disease and nearly zero in patients with autonomous adenoma. Early results of 125I therapy of Graves' disease are presented. Peculiar aspects of thyroid function after destructive therapy of Graves' disease are discussed.